medigraphic.com
ISSN 1405-8871 (Print)

2016, Number 4

<< Back Next >>

Aten Fam 2016; 23 (4)

Treatment to Patients with Acute Diarrhea: Survey to a Group of General Practitioners from Mexico

Bielsa-Fernández MV, Frati-Munari AC, Ariza-Andraca R

Language: Spanish
References: 27
Page: 119-124
PDF size: 376.82 Kb.


ABSTRACT

Objective: to know the clinical features and treatment in cases of acute diarrhea given by General Practitioners in Mexico. Methods: during 2015 it was conducted a survey with general practitioners from 26 cities of Mexico. Results: 109 medical provided data of 1 840 patients with acute diarrhea, from 1 to 98 years of age (media 34 years), 90% had less than 48 hours of evolution of a media of six evacuations a day, liquid or semi-liquid; 37% mucus or blood in the stool, 41.9% fever, 38.7% of the patients had previously received treatment with antimicrobials and/ or antidiarrheal. The prescribed treatment was oral (93%) and intravenous (7%) hydration; antimicrobial (90.7%), mostly Rifaximin (75.6%); in 17.6% the combination of antimicrobials were prescribed. Probiotics were prescribed to 57.1%; and antidiarrheal to 23%. In all cases the diarrhea disappeared within four days or less. A relationship between treatments and therapeutic response was not established since most patients received antimicrobials. Conclusions: the treatment of acute diarrhea prescribed by the interviewed physicians was: oral hydration, antibiotics (mainly Rifaximin) and probiotics. In all cases diarrhea disappeared within four days or less.


REFERENCES

  1. suive/dge/salud/Información epidemiológica de morbilidad. Anuario 2011 [Internet]. [Citado 2015 Oct 21]. Disponible en: http:// www.epidemiologia.salud.gob.mx/doctos/ infoepid/publicaciones/2012/ver_ejecutiva_ 2011.pdf

  2. Novoa-Farías O, Frati-Munari AC, Peredo MA, Flores-Suarez S, Novoa-García O, Galicia-Tapia J, et al. Susceptibilidad de las bacterias aisladas de infecciones gastrointestinales agudas a la rifaximina y otros agentes Bielsa-Fernández MV y cols. antimicrobianos en México. Rev Gastroenterol Mex. 2016;81:3-10.

  3. Hernández Cortez C, Aguilera Arreola MG, Castro Escarpulli G. Situación de las enfermedades gastrointestinales en México. Enf Inf Microbiol. 2011;31:137-51.

  4. Velazquez FR, Calva JJ, Guerrero ML, Mass D, Glass RI, Pickering LK, et al. Cohort study of rotavirus serotype in symptomatic and asymptomatic infections in mexican children. Pediat Infect Dis J. 1993;12:54-61.

  5. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med. 1996;335:1022-8.

  6. Secretaría de Salud, Dirección General de Epidemiología. Manual de procedimientos estandarizados para la vigilancia epidemiológica de las enteritis por Rotavirus. [Internet]. [Citado 2015 oct 20]. Disponible en: www. Epidemiologia.salud.cob.mx/doctos/infoepid/ vig_epid_manuales/25_Manual_ROTAVIRUS_ vFinal_8nov12.pdf

  7. Centro para el control y prevención de enfermedades. cdc 24/7.acerca del rotavirus [Internet]. [Citado 2015 Oct 21]. Disponible en: www. cdc.gov/rotavirus/about/symptoms-sp.html

  8. Guía de práctica clínica. Prevención, diagnóstico y tratamiento de la diarrea aguda en niños de dos meses a cinco años en el primero y segundo nivel de atención. Catálogo maestro de guías de práctica clínica. SSA-156-08. [Internet], [Citado 2015 Oct 23]. Disponible en: www.cenetec.salud.gob.mx

  9. Gutiérrez G, Tapia Conyer R, Kumate J. Impact of oral rehydration and selected public health interventions on reduction on mortality from childhood diarrheal diseases in Mexico. Bull World Health Org. 1996;74:189-97.

  10. Guía de práctica clínica. Atención, diagnóstico y tratamiento de la diarrea aguda en adultos en el primer nivel de atención. Catálogo maestro de práctica clínica SSA 106-08 [Internet]. [Citado 2015 Oct 28]. Disponible en: www. cenetec.salud.gob.mx

  11. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73(suppl 1):13-27.

  12. Brown LE, Xue Q, Jiang ZD, Xu Y, DuPont HL. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agent Chemother. 2010;54:388-96.

  13. Fiorucci S, Distrutti E, Mencarelli A, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66:246-56.

  14. DuPont HL. Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases. Mayo Clin Proc. 2015;90:1116-24.

  15. DuPont H, Haake R, Taylor DN, Ericsson CD, Jiang ZD, Okhuisen PC, et al. Rifaximin treatment of pathogen-negative travelers’ diarrhea. J Trav Med. 2007;14:16-9.

  16. Capello F, Gaddi AV. Efficacy and Safety of rifaximin in acute gastroenteritis in children: a meta-analysis. ierj. 2016;2:117-22.

  17. Cohen SH, Gerding DN, Johnson S, Kelly CP, LooVG, McDonald LC, et al. Guías de práctica clínica para la infección por Clostridium difficile en adultos: actualización 2010 realizada por la Sociedad Epidemiológica de Norteamérica (shea) y la Sociedad de Enfermedades Infecciosas de Norteamérica (idsa). Infect Control Hosp Epidemiol. 2010;31:T1- T28.

  18. Johnson S, Schriever C, Galang M. Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. cid. 2007;44:846-8.

  19. Patrick Basu P. Rifaximin therapy for metronidazole unresponsive Clostridium difficile infection: a prospective trial. Therap Adv Gastroenterol. 2010;3:221-5.

  20. Jernberg C, Löfmark S, Edlund C, Janson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010;156:3216-23.

  21. Ferrer M, Martins dos Santos VAP, Ott SJ, Moya A. Gut microbiota disturbance during antibiotic therapy. A multi-omic approach. Gut Microbes. 2014;5:64-70.

  22. Kakobsson HE, Jernberg C, Anderson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human thrpat anf gut microbiome. PLoS One. 2010;5:e9836.

  23. Young RJ, Huffmans S. Probiotic use in children. J Pediatr Care. 2003;17:277-83.

  24. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev. 2003;16:658-72.

  25. Leahey SC, Higgins DG, Fitzgerald GF, Van Sinderen D. Getting better with bifidobacteria. J Appl Microbiol. 2005;98:1303-15.

  26. Kolida S, Gibson GR. Synbiotics in health and disease. Annu Rev Food Sci Technol. 2001;2:373-93.

  27. Rimon A, Freedman SB. Recent advances in the treatment of acute gastroenteritis. Clin Pediatr Emerg Med. 2010;11:162-70.




2020     |     www.medigraphic.com